Smart drug targets two cancer weaknesses at once
Disease control
Not yet recruiting
This trial tests a new drug called AN4035 in people with advanced solid tumors that have RAS mutations and high levels of the CEACAM5 protein. The drug is designed to seek out cancer cells carrying CEACAM5 and deliver a payload that blocks RAS, a key driver of cancer growth. The …
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC